AbbVie and Momenta announce Humira patent licence agreement
08-11-2018
AbbVie and Amgen settle Humira clash
29-09-2017
miodrag ignjatovic / iStockphoto.com
AbbVie has secured another settlement relating to litigation over Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AbbVie, Samsung Bioepis, Humira, patent infringement, settlement, litigation, biosimilar
